%20(1)_edited_p.png)
Oct 27, 2026
Consumers
SNDL Stock Analysis: “A Record With an Asterisk” — Can Buybacks Outrun the Business?
Oct 23, 2026
Energy and Utilities
GRC Stock Analysis: “Record Everything” — Margin Machine or Backlog Burn?
Sep 02, 2026
Tech
DAKT Stock Analysis: “Margins Up, Orders Down” — Operating Leverage or Thinning Backlog?
Aug 17, 2026
BioTech
HRMY Stock Analysis: "Wakix Momentum" Revisited — Billion-Dollar Year or Orexin Reckoning?
Why Choose Small Cap Newsroom?
Our team blends finance know-how with a passion for storytelling.
Insights You Can Use
Stay ahead with our expert analysis and tips.
Expertise You Can Rely On
Our team of experts brings years of experience.
Smart, Engaging & Informative
Enjoy engaging articles that make learning fun.
Essential Resources for Small-Cap Investors
Build your toolkit with guides, checklists, and recommendations made for small-cap investors.
In The Spotlight
In the Spotlight: CRMD’s (NASDAQ: CRMD) Commercial Surge—The Quest for
Blockbuster Status in Infection Prevention
CorMedix (CRMD) has shifted from a cash-burning biotech to a rapidly scaling commercial player following FDA approval of DefenCath, with Q3 2025 results confirming explosive revenue growth, a swing to profitability, and strong outpatient adoption. Management is pushing aggressive expansion, aiming for over $400 million in U.S. sales by 2028, though the path forward carries risks—from adoption hurdles and policy shifts to competition and rising costs. The investment story now hinges on whether CRMD can maintain DefenCath’s momentum, expand margins, and execute flawlessly as it transitions from speculative biotech to a true infection-prevention powerhouse.
